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Abstract
Quantification of intra-epidermal nerve fibers (iENFs) is an important approach to stage diabetic
peripheral neuropathy (DPN) and is a promising clinical endpoint for identifying beneficial
therapeutics. Mechanistically, diabetes decreases neuronal mitochondrial function and enhancing
mitochondrial respiratory capacity may aid neuronal recovery from glucotoxic insults. We have
proposed that modulating the activity and expression of heat shock proteins (Hsp) may be of
benefit in treating DPN. KU-32 is a C-terminal Hsp90 inhibitor that improved thermal hypoalgesia
in diabetic C57Bl/6 mice but it was not determined if this was associated with an increase in iENF
density and mitochondrial function. After 16 weeks of diabetes, Swiss Webster mice showed
decreased electrophysiological and psychosensory responses and a >30% loss of iENFs.
Treatment of the mice with ten weekly doses of 20 mg/kg KU-32 significantly reversed pre-
existing deficits in nerve conduction velocity and responses to mechanical and thermal stimuli.
KU-32 therapy significantly reversed the pre-existing loss of iENFs despite the identification of a
sub-group of drug-treated diabetic mice that showed improved thermal sensitivity but no increase
in iENF density. To determine if the improved clinical indices correlated with enhanced
mitochondrial activity, sensory neurons were isolated and mitochondrial bioenergetics assessed ex
vivo using extracellular flux technology. Diabetes decreased maximal respiratory capacity in
sensory neurons and this deficit was improved following KU-32 treatment. In conclusion, KU-32
improved physiological and morphologic markers of degenerative neuropathy and drug efficacy
may be related to enhanced mitochondrial bioenergetics in sensory neurons.
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Diabetic peripheral neuropathy (DPN) is a common neurodegenerative complication of
diabetes that has proven difficult to manage pharmacologically due to its multifactorial
etiology (Yorek, 2011). Despite the efficacy of a plethora of small molecule inhibitors that
target a single etiologic contributor to DPN in rodent models, the biochemical and temporal
complexity underlying the progression of DPN in humans has proved challenging for
translating the success in animal models to its clinical management (Calcutt et al., 2009).
Thus, considerable need exists to identify novel pharmacologic targets or therapeutic
paradigms that, in combination with good glycemic control, will help patients overcome the
difficulties of slowing or reversing the progression of DPN. Examples of such approaches
lie in improving dyslipidemia (Vincent et al., 2009), using a dual specificity vasopeptidase
inhibitor to block angiotensin converting enzyme and neutral endopeptidase to improve
neural and vascular deficits in DPN (Yorek, 2008) and the recent demonstration that
hydroxyflavones may target multiple mechanisms that contribute to DPN (Stavniichuk et al.,
2011). An additional and relatively unexplored paradigm is that pharmacologically
modulating the activity of molecular chaperones will promote a broadly cytoprotective
response that improves psychosensory, electrophysiological, biochemical and morphological
indices of DPN.
Heat shock proteins 90 and 70 (Hsp90 and Hsp70) are two molecular chaperones that are
critical for the proper folding of nascent proteins. Many neurodegenerative diseases (for
example, Alzheimer's and Parkinson's disease) can be considered as protein-conformational
disorders since the accumulation of specific mis-folded or aggregated proteins is a primary
contributor to their etiology (Muchowski and Wacker, 2005). Although the accumulation of
any one specific misfolded or aggregated protein is not associated with the development of
DPN, hyperglycemia can increase the oxidative modification of amino acids (Akude et al.,
2009; Obrosova, 2009) leading to impairments in protein folding (Muchowski and Wacker,
2005), increased interaction with molecular chaperones (Pratt et al., 2010) and decreased
mitochondrial function (Fernyhough et al., 2010). Moreover, Hsp70 and Hsp90 are also
components of the cellular heat shock response (HSR). Numerous conditions that promote
cell stress lead to the Hsp90-dependent induction of the HSR which, in part, promotes the
transient up-regulation of Hsp70 to aid the refolding or clearance of aggregated and
damaged proteins (Pratt et al., 2010). Hsp70 upregulation can also prevent neuronal
apoptosis (Bienemann et al., 2008) and decrease oxidative stress in neurodegenerative
disorders (Chaudhury et al., 2006). Importantly, pharmacologic inhibitors ofHsp90 can
induce Hsp70 and have shown potential in treating neurodegenerative diseases (Luo et al.,
2007) and DPN (Urban et al., 2010).
Hsp90 contains a C-terminus ATP binding domain that weakly binds the antibiotic
novobiocin (Marcu et al., 2000). Through systematic modification of the coumarin ring
pharmacophore of novobiocin, KU-32 (Fig. 1) was identified as a C-terminal Hsp90
inhibitor whose ability to promote a heat shock response requires an acetamide substitution
on the coumarin ring (Matts et al., 2011). Consistent with this effect, KU-32 protected
against glucose-induced death of unmyelinated embryonic sensory neurons and ameliorated
neuregulin-induced demyelination of myelinated Schwann cell and sensory neuron co-
cultures in an Hsp70 dependent manner (Urban et al., 2010). Importantly, KU-32 is readily
bioavailable and weekly treatment of diabetic mice with 20 mg/kg KU-32 reversed multiple
clinical indices of DPN, including thermal hypoalgesia. Loss of thermal sensation in the feet
involves dysfunction or loss of small intra-epidermal nerve fibers (iENF) that respond to
thermal stimuli (Beiswenger et al., 2008a, 2008b). Loss of iENFs has been reported in both
Type 1 and Type 2 diabetics (Boucek et al., 2005; Pittenger et al., 2005) as well as
individuals with impaired glucose tolerance (Smith et al., 2001). Thus, interventions that can
improve fiber recovery or preserve the function of remaining fibers may be particularly
beneficial to help manage human DPN. However, diabetic rodents can show pharmacologic
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recovery of thermal sensation in the absence of appreciable increases in iENF density
(Obrosova et al., 2010; Stavniichuk et al., 2011). In our previous study, it was unclear if the
recovery of thermal sensitivity after KU-32 treatment was associated with an increase in
iENF density since untreated diabetic mice did not exhibit a significant loss of iENFs
(Urban et al., 2010). Additionally, though the efficacy of KU-32 required expression of
Hsp70, little insight was gained into how KU-32 may affect neuronal physiology. It is well
appreciated that increased oxidative stress and mitochondrial dysfunction contribute to the
pathogenesis of DPN (Chowdhury et al., 2011; Obrosova, 2009). We have shown recently
that prolonged diabetes downregulated numerous mitochondrial proteins in dorsal root
ganglia and that decreases in the mitochondrial proteome correlated with a decrease in
mitochondrial respiratory capacity (Akude et al., 2011; Chowdhury et al., 2011). Therefore,
the current study addressed whether the improvement in DPN by KU-32 is associated with a
recovery of iENF density and an enhanced bioenergetic profile of adult sensory neurons
using Swiss Webster mice as a genetically outbred strain that develops severe DPN and
shows rapid changes in iENF density in response to STZ-induced diabetes (Beiswenger et
al., 2008a, 2008b; Kennedy and Zochodne, 2005).
Methods
Materials
Streptozotocin (STZ), carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone (FCCP),
oligomycin and poly-DL-ornithine were obtained from Sigma-Aldrich (St. Louis, MO).
KU-32, [N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-
pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)acetamide], was synthesized and
structural purity (>95%) verified as described (Huang and Blagg, 2007). Collagenase and
laminin were obtained from Gibco/Invitrogen (Carlsbad, CA).
Induction of diabetes and drug treatments
Six-week old, outbred Swiss Webster mice were purchased from Harlan Laboratories
(Indianapolis, IN) and diabetes induced at 8 weeks of age. After 6 h of food withdrawal,
mice were injected with 100 mg/kg STZ dissolved in 0.2 ml of sterile 0.1 M sodium citrate
in phosphate buffered saline. The STZ injection was repeated the next day and control mice
received two injections of the vehicle. One week after the last injection, mice with fasting
blood glucose (FBG) >290 mg/dl (One-Touch Ultra glucometer) were deemed diabetic.
After 16 weeks, control and diabetic animals were given a once per week intra-peritoneal
injection (0.2 ml) of 5 mM Captisol (CyDex Pharmaceuticals, Lenexa, KS) or 20 mg/kg
KU-32 in 5 mM Captisol for 10 weeks. All animals were maintained on a 12 h light/dark
cycle with ad libitum access to water and Purina diet 5001 rodent chow. FBG and HbA1c
levels (A1C Now+) were determined prior to euthanizing the animals.
All animal procedures were performed in accordance with protocols approved by the
Institutional Animal Care and Use Committee (IACUC) and in compliance with standards
and regulations for care and use of laboratory rodents set by the National Institutes of
Health. To comply with veterinary oversight and IACUC approval, we also employed a
body condition score (BCS) to assess an overall decline in body condition that was unlikely
to spontaneously improve (Ullman-Cullere and Foltz, 1999). In a mouse, a BCS1 indicates
advanced muscular wasting and extreme loss of subcutaneous fat deposits yielding
prominent indentations between vertebrae and sharp protuberances of spinal processes, the
ileum and sacrum. This is an extreme that we tried to avoid since death would be imminent.
A mouse of BCS1+ status had less severe fat loss and with milder bony protuberances. If the
mouse showed hunched posture, closed or sunken eyes and was lethargic, this was all taken
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into consideration in conjunction with a veterinary consult to euthanize the animal since it
was unlikely to spontaneously improve.
Measures of nerve conduction velocity (NCV), mechanical and thermal sensitivity
Motor (MNCV) and sensory (SNCV) NCV measurements were performed on deeply
anesthetized mice using a TECA™ Synergy N2-EMG Monitoring System as we have
previously described in detail (McGuire et al., 2009). A Dynamic Plantar Aesthesiometer
(Stoelting Inc., Wood Dale, IL) fitted with a stiff monofilament was used to assess
mechanical sensitivity. Preliminary experiments indicated that applying the filament to the
plantar surface at an upward force of 10 g was necessary to provide a sufficient dynamic
range to detect mechanical hypoalgesia in the diabetic Swiss Webster mice. Thermal
sensitivity was assessed by paw withdrawal latency to a ramping focal radiant heat using a
Hargreaves Analgesiometer (Stoelting Inc., Wood Dale, IL) (Hargreaves et al., 1988).
Responses from each animal were measured 3–4 times on alternate feet and averaged
(McGuire et al., 2009).
Intra-epidermal nerve fiber analysis
The plantar surface of both hind paws was dissected and placed in Zamboni's fixative
overnight. Tissues were rinsed in PBS, cryoprotected in 30% sucrose overnight at 4 °C,
embedded in OCT, frozen on dry ice, and stored at −80 °C. Frozen tissues were sectioned at
30 µm, placed on Superfrost Plus microscope slides, coded to obscure treatment and stored
at −80 °C. Immunohistochemistry was performed using an anti ubiquitin C-terminal
hydrolase (PGP 9.5) antibody (AbD Serotec, Oxford, UK) and the Vectastain Elite ABC-
Peroxidase kit (Vector Laboratories, Burlingame, CA). Slides were incubated in blocking
buffer containing normal goat serum for 30 min, incubated in a 1:1000 dilution of anti-PGP
9.5 antibody for 3 h at room temperature, rinsed in PBS, and incubated with secondary
antibody for 1 h at room temperature. Slides were rinsed in PBS, incubated with an avidin–
biotin complex solution (ABC solution) for 1 h at room temperature, rinsed and incubated in
NovaRED peroxidase substrate solution for 2–3 min. Sections were counterstained with
hematoxylin and a cover slip applied. Twelve digital images per animal were captured at
40× magnification using a Zeiss light microscope with a color CCD camera. Single nerve
fibers crossing the dermal/epidermal junction were counted (intra-epidermal branches were
disregarded) from each image by two observers blinded to treatment (Lauria et al., 2005).
The iENF density was calculated by the number of fibers divided by the length of the
dermal/epidermal junction (fibers/mm). The effect of the treatments on sub-epidermal fibers
was estimated by tracing individual PGP 9.5-positive fibers and summing the fiber area
using Image J. The percent of the dermal area occupied by the fibers was determined by
dividing by the total sub-epidermal area.
Isolation of adult sensory neurons
Adult sensory neurons were isolated as described with minor modifications (Delree et al.,
1989). Mice were euthanized via CO2 overdose, the spinal column dissected and the spinal
cord dislodged with a gentle stream of PBS delivered with a 10 ml syringe. The L4–L6
dorsal root ganglia (DRG) from 3 mice per treatment were removed and pooled together in
Ham's F10 medium containing 10% fetal calf serum(FCS) (Atlas Biologicals, Fort Collins,
CO). After removing connective tissue and trimming the nerve stumps, ganglia were placed
in 1 ml serum-free F10 medium. The cleaned ganglia were dissociated by the addition of 1
ml of 1.25% collagenase for 45 min at 37 °C followed by a second digestion with 1 ml of
2% trypsin for 30 min at 37 °C. Cells were isolated by centrifugation at 1000 ×g for 5 min
and the pellet further dissociated by triturating in F10 medium with a fire-polished glass
pipette. The cell suspension was layered on a 10 ml gradient of sterile iso-osmotic Percoll
(0.9 ml of 10× PBS, 6.485 ml ddH2O, 2.615 ml Percoll) and centrifuged at 800 ×g for 20
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min to remove cell debris and myelin fragments. The cell pellet was resuspended in fresh
F10 medium, passed through a 40 µm nylon mesh and the filter washed with 5 ml of serum
free medium. The cells in the filtrate were recovered by centrifugation and resuspended in
F10 medium (6.1 mM glucose) containing N2 supplement (Invitrogen) without insulin.
Neurons were plated onto poly-DL-ornithine (0.1 mg/ml overnight)/laminin (2 µg/ml for 3 h)
coated 96 well plates at 5×103 cells/well.
Measuring mitochondrial respiration in intact adult sensory neurons
Oxygen consumption rate (OCR) was assessed using intact adult DRG sensory neurons and
an XF96 Extracellular Flux Analyzer (Seahorse Biosciences, North Billerica, MA) (Wu et
al., 2007). Following isolation, adult sensory neurons were incubated for two days in F10
medium containing N2 supplement. Prior to assessing OCR, the neurons were placed in
fresh bicarbonate-free DMEM containing 5.5 mMglucose and incubated for 1 h at 37 °C.
Baseline OCR was assessed in the XF96 analyzer using 4 measurement loops consisting of a
2 min mix cycle and a 5 min measurement cycle. Respiratory chain inhibitors were then
sequentially injected into the wells and ATP-coupled oxygen consumption was calculated as
the fraction of the basal OCR sensitive to 1 µg/ml oligomycin, an ATP synthase inhibitor.
The maximal uncoupled respiration rate was determined by depolarizing the mitochondrial
membrane potential with 1 µM FCCP; inhibitor concentrations were optimized in
preliminary experiments. After the respiratory measures, the cells were harvested and
experimental rate values were normalized to protein content of each well. Maximal and
spare respiratory capacities were determined from the rate data as described (Brand and
Nicholls, 2011; Sansbury et al., 2011).
Statistical analyses
Data are presented as mean ± SEM. After verifying equality of variance, differences
between treatments were determined using a one or two-way ANOVA and Tukey's test; if
appropriate, a non-parametric analysis was used.
Results and discussion
After 26 weeks of untreated diabetes, body weight was significantly decreased relative to
control mice and as expected, both FBG and HbA1c were significantly elevated (Table 1).
After 16 weeks of diabetes, KU-32 was administered weekly for 10 weeks and did not
significantly change body weight, FBG or HbA1c levels relative to untreated diabetic
animals. These results are similar to those observed in diabetic C57Bl/6 mice (Urban et al.,
2010) and indicate that the dose and drug schedule are insufficient to improve overall
glycemic control. It is interesting to note that during the period of KU-32 therapy, 7 of 15
untreated diabetic mice abruptly died (4) or required early euthanizing (3) for humane
reasons due to a poor body condition score. However, only 3 of 14 diabetic animals
receiving KU-32 were euthanized early due to a poor body condition score.
KU-32 improves electrophysiologic, psychosensory and morphologic indices of DPN
After 16 weeks of diabetes, MNCV decreased from 58.6 ± 1.0 to 48.9 ± 2.0 m/s (p<0.001, n
= 4) in the diabetic mice; the effect of diabetes on SNCV was more modest, 40 ± 0.1 to 36.2
± 1.1 m/s (p<0.05, n = 4). After 26 weeks of untreated diabetes, both MNCV and SNCV
remained significantly decreased compared to control (Fig. 2A). Although MNCV decreased
another 15% (41.3 ± 4.1 m/s) compared to the 16 week time point, weekly treatment with 20
mg/kg KU-32 prevented this decline and reversed the pre-existing deficit in MNCV.
Similarly, KU-32 also reversed the slowing observed in SNCV (Fig. 2A).
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Mechanical and thermal sensitivity were measured on alternate weeks beginning 4 weeks
after the onset of hyperglycemia. After initiating KU-32 therapy, sensory assessments were
then taken weekly. Although the force necessary to induce paw withdrawal remained around
5.5 g in control mice, diabetic Swiss Webster mice exhibited a significant decline in
mechanical sensitivity after 4 weeks. This mechanical hypoalgesia steadily worsened until
18 weeks of diabetes and reached a plateau of around 9.5 g for the duration of the
experiment (Fig. 2B). Relative to untreated diabetic mice, KU-32 induced a time-dependent
improvement in mechanical sensitivity after 1 week of treatment. Following six weeks of
drug treatment, the force required to induce paw withdrawal was indistinguishable from
control animals. KU-32 had no effect on mechanical sensitivity in non-diabetic mice.
Diabetic Swiss Webster mice also showed a significant increase in paw withdrawal latency
to a thermal stimulus after 5 weeks and this reached a plateau between 15 and 24 weeks
(Fig. 2C). KU-32 treatment had no effect on thermal sensitivity in non-diabetic control mice
but promoted a significant, time-dependent decrease in paw withdrawal latency in diabetic
mice. However, this improvement was only indistinguishable from control animals after 10
weeks of treatment. Thus, although KU-32 therapy improved psychosensory detection of
both mechanical and thermal stimuli, the slopes of the recovery curves support that the rate
and magnitude of these changes differ.
Improvements in thermal sensitivity may occur in the absence of a recovery of iENFs
(Beiswenger et al., 2008a, 2008b; Chen et al., 2005; Stavniichuk et al., 2011). Prior to drug
treatment, diabetic Swiss Webster mice showed a 31% decline in iENFs that crossed the
dermal/epidermal junction (n = 4) (Figs. 3A and B). This deficit allowed us to assess
whether modulating molecular chaperones may improve this morphologic index of DPN and
assess its correlation with improved thermal sensitivity. At study termination, the decrease
in iENF density in untreated diabetic mice was 29%. Non-diabetic mice treated with KU-32
showed no difference in iENF density compared to control mice. In contrast, modulating
molecular chaperones in the diabetic mice led to a partial, but significant, recovery of iENF
density. Next, each animal's response latency to a thermal stimulus was plotted against its
iENF density. Consistent with a prior study (Beiswenger et al., 2008a, 2008b), a significant
inverse correlation was observed between untreated diabetic animals and both non-diabetic
control groups (p<0.0001, r2 = 0.6872) (Fig. 3C). Compared to the untreated diabetic mice,
all drug-treated diabetic animals showed a significant improvement in thermal sensitivity.
However, k-means cluster analysis identified a subgroup of drug-treated diabetic animals
that statistically clustered with the untreated diabetic mice. This subgroup of 4 mice showed
significantly fewer fibers compared to the 7 remaining drug-treated diabetic mice (p<0.006,
Mann–Whitney test) but still showed a significant improvement in thermal hypoalgesia.
Despite this group of non-responders, the iENF density in the remaining drug-treated
diabetic animals was similar to the control groups. Unfortunately, the underlying reason why
this subgroup did not respond to the drug is unclear. One possibility is that it may be related
to the genetic heterogeneity associated with the outbred strain, but a larger sample size will
be needed to determine if this may be the case. Nonetheless, these results strongly support
that KU-32 therapy can reverse a pre-existing deficit in iENF density. Since the amount of
fiber loss at 16 and 26 weeks in the untreated diabetic mice was similar, this would argue
against the drug diminishing the rate of progressive fiber degeneration. Thus, KU-32 may
improve thermal sensitivity by helping to promote small fiber regeneration and/or by
decreasing the loss of TRPV1 heat-sensor receptors that is observed in diabetic mice with
thermal hypoalgesia (Pabbidi et al., 2008). Unfortunately, the primary chaperone that
mediates TRPV1 folding and trafficking is unknown (Niemeyer, 2005).
Lastly, we assessed whether the dermal nerve fibers were affected by the treatments. The
percent area occupied by PGP9.5 positive dermal fibers was normalized to total dermal area
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and although diabetes trended toward decreasing dermal fiber area, no significant
differences were observed (Veh + Veh, 5.9 ± 1.0%; Veh + KU-32, 5.7 ± 1.9%; STZ + Veh,
4.8 ± 1.7%; STZ + KU-32, 5.2 ± 1.1%).
KU-32 improved mitochondrial bioenergetics in adult sensory neurons
Enhanced oxidative stress and diminished mitochondrial function contribute to the
pathogenesis of DPN (Chowdhury et al., 2011; Fernyhough et al., 2010; Obrosova, 2009).
We have recently shown that numerous mitochondrial proteins are downregulated in dorsal
root ganglia obtained from diabetic rats and that a decrease in mitochondrial respiration
correlated with the diabetes-induced alterations in the mitochondrial proteome (Akude et al.,
2011). Therefore, we examined whether the efficacy of KU-32 was associated with
improving neuronal mitochondrial function.
Adult sensory neurons were isolated from lumbar DRG since they provide the axons for the
myelinated and unmyelinated fibers that are affected in DPN, and whose physiology and
morphology was improved by KU-32. An important advantage of adult sensory neurons is
that they have been exposed to the physiological milieu of diabetes and exhibit molecular
deficits associated with a “diabetic phenotype” (Huang et al., 2003, 2005; Vincent et al.,
2010; Zherebitskaya et al., 2009). The ex vivo use of intact neurons also avoids artifacts
associated with mitochondrial isolation from DRG. However, since the cultures are not
pulsed with anti-mitotics, it is not possible to remove all contaminating Schwann cells and
fibroblasts from the cultures (Fig. 4A), as is customary when using embryonic sensory
neurons (Yu et al., 2008). Nevertheless, the enriched neuronal preparation readily elaborates
neurites (Fig. 4A) and maintains a neuronal phenotype for a bioenergetic analysis as also
reported by others (Chowdhury et al., in press).
Oxygen consumption rate (OCR) of intact adult sensory neurons was measured in real time
using a XF96 Extracellular Flux Analyzer. An example of a typical mitochondrial function
experiment of sensory neurons respiring in medium containing 5.5 mM glucose is shown in
Fig. 4B. The initial four rates provide a measure of the cells basal OCR (light blue shading);
rate measures are expressed as a percent of the final basal OCR (rate 4) after normalizing to
the total amount of protein per well. Respiratory chain poisons are used to assess
mitochondrial dysfunction (Brand and Nicholls, 2011) and the addition of oligomycin (ATP
synthase inhibitor) decreases the basal OCR. The portion of basal OCR that is coupled to
ATP synthesis (dark blue shading) is estimated by the magnitude of this decrease and any
residual OCR is from uncoupled respiration (proton leak). Maximal respiratory capacity
(MRC, red shading) assesses the functional integrity of the respiratory chain once electron
transfer is no longer limited by the proton gradient across the inner mitochondrial membrane
(Brand and Nicholls, 2011). This is achieved following exposure to the protonophore,
FCCP. Spare respiratory capacity (SRC) provides a functional indication of how close to its
bioenergetic limit a cell is respiring and is estimated as the arithmetic difference between
MRC and the basal OCR (purple shading) (Brand and Nicholls, 2011; Nicholls et al., 2007).
A loss of SRC increases the susceptibility of cells to secondary stressors since it limits the
dynamic range available to match energy output with environmental demands (Choi et al.,
2009; Dranka et al., 2010). Thus, treatment-related differences in MRC and SRC reflect
alterations in the bioenergetic limits and reserve capacity of the neurons. The green shading
is representative of non-mitochondrial OCR values obtained after the addition of rotenone
and antimycin A to inhibit complexes I and III, respectively.
At study termination, the neurons were isolated and used to assess OCR two days
afterwards. After establishing the baseline OCR, the cells were treated with 1 µg/ml
oligomycin to inhibit ATP synthase. In neurons obtained from animals treated with vehicle,
the decrease in OCR indicated that ~35% of basal respiration was directed toward ATP
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synthesis (Fig. 4C). In other words, this level of ATP-coupled respiration is sufficient to
maintain ATP/ADP levels in control neurons. In contrast, the increase in oligomycin-
sensitive OCR in diabetic neurons suggests that more of the basal OCR is directed toward
ATP synthesis. This may reflect the damaged electron transport capacity of the mitochondria
which necessitate that more of the total OCR be directed toward ATP production to meet
cellular demands. Importantly, neurons from diabetic mice treated with KU-32 showed a
significant recovery in oligomycin-sensitive OCR with about 40% of the basal OCR now
coupled to ATP production (Fig. 4C). Integrating the area under the curve for rates 4–7
indicated that diabetes significantly affected oligomycin-sensitive OCR relative to control
and this was partially but significantly reversed in the KU-32 treated diabetic mice (Fig.
4D). Although FCCP stimulated MRC above baseline in neurons from both control and
KU-32 treated animals, this response was blunted in diabetic neurons, consistent with the
mitochondria being at their energetic limit. However, KU-32 treatment modestly but
significantly, improved MRC as determined by integrating the area under the curve for rates
7–11 (Fig. 4D). However, in neither diabetic group did the MRC exceed the basal OCR (rate
3) as was seen in the control cells. Thus, the mitochondria have no SRC to aid the response
to additional stress. That diabetes blunted the MRC and abolished SRC suggests that the
cells are energetically stressed and that mitochondrial workload is increased. Although
mitochondrial function was not completely recovered with KU-32 therapy, this nonetheless
correlates with a reversal in the sensory deficits. Lastly, it should be noted that one
limitation in our approach was the inability to assess non-mitochondrial OCR in the same
well due to the limited number of cells and current technical limitations of the XF96
instrument. Although it is likely that non-mitochondrial OCR increased in the diabetic mice
(Chowdhury et al., in press), this does not detract from the decrease observed in MRC and
SRC.
Conclusions
The results from the current study support our proposal that modulating molecular
chaperones may afford a novel approach to manage human DPN (Urban et al., 2010). The
efficacy of the intervention strategy suggests that the ability of KU-32 to improve iENF
density may be of clinical usefulness since abnormalities and loss of small sensory fibers
can precede damage to larger myelinated fibers in human DPN (Malik et al., 2011). A
second novel finding relates to the effect of KU-32 on improving mitochondrial function.
After 26 weeks of diabetes, sensory neurons showed a markedly diminished maximal
respiratory capacity which is consistent with previous reports that diabetes decreased
numerous mitochondrial proteins, lowered respiratory rates (Akude et al., 2011; Chowdhury
et al., 2010) and diminished both maximal and spare respiratory capacity in diabetic adult
sensory neurons (Chowdhury et al., in press). KU-32 treatment modestly, but significantly,
improved this deficit in respiratory capacity. However, further work will be necessary to
determine if the partial recovery of mitochondrial function is a contributor to or consequence
of the substantially improved sensory measures.
Although little is known on the effect of diabetes on Hsp70 expression and function in
peripheral nerve, Hsp27 and Hsp70 were increased in DRGs after four months of diabetes in
the Bio-breeding/Worcester (BB/Wor) rats, a model of type 1 diabetes (Kamiya et al., 2005).
On the other hand, a decrease in Hsp70 levels in DRG correlated with the development of
neuropathy and a loss of myelinated and unmyelinated fibers after ten months of
hyperglycemia in BB/Wor rats, (Kamiya et al., 2006). However, decreased expression of
Hsp70 is not essential for the development of DPN since diabetic mice lacking the inducible
isoforms of Hsp70 (Hsp70.1 and 70.3) readily developed an insensate neuropathy (Urban et
al., 2010). Conceivably, increased expression of Hsp70 may represent an early
cytoprotective response that dwindles due to the excessive metabolic disturbances associated
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with poorly controlled diabetes. Interestingly, a recent analysis of over 500 Type 1 diabetics
from the EURODIAB Study found that elevated anti-Hsp70 antibody levels are associated
with a 50% lower likelihood of micro/macrovascular diabetic complications, independent of
inflammation and other risk factors (Gruden et al., 2009). Although it remains unclear if
Hsp70 antibodies contribute to diabetic complications or serve primarily as a biomarker,
these data suggest that secretion of Hsp70 may be cytoprotective and associated with
decreased risk of diabetic complications. Consistent with this possibility, neuronal uptake of
Hsp70 secreted from glia decreased cell death induced by trophic factor withdrawal
(Guzhova et al., 2001). Since diabetic Hsp70 knockout mice were unresponsive to KU-32
therapy, its neuroprotective properties hinge on the presence of Hsp70 (Urban et al., 2010).
Together, these data support that modulating the expression of Hsp70 can ameliorate aspects
of hyperglycemic stress and improve diabetic complications such as neuropathy.
It is well regarded that maintaining axonal plasticity of small epidermal fibers requires a
continuous and available ATP supply (Chowdhury et al., 2011) and that defects in
mitochondrial proteins such as bcl-w(Courchesne et al., 2011) can promote a sensory
neuropathy. Thus, Hsp70 induction and improved mitochondrial bioenergetics may aid
small fiber recovery. Consistent with this outcome, over-expression of Hsp70 in rat heart
improved mitochondrial respiration and decreased mitochondrial damage in an ischemia/
reperfusion injury (Bu et al., 2002). Similarly, in mouse skeletal muscle, transgenic over-
expression of Hsp70 enhanced mitochondrial enzyme activity (Chung et al., 2008). Under
conditions of glucose-deprivation, Hsp70 overexpression in astrocytes inhibited proton leak
in the electron transport chain and accumulation of reactive oxygen species (Ouyang et al.,
2006). Notably, a folding competent chaperone may not be required for protection since an
ATPase-deficient Hsp70 mutant was just as protective as the wild type protein (Ouyang et
al., 2006). Thus, Hsp70 may function as part of a protein complex to affect mitochondrial
physiology and recent work has uncovered that cytosolic Hsp70 and Hsp90 are part of a
multiplex transporter that mediates mitochondrial import of nuclear-encoded proteins via
interaction with Tom70 (Young et al., 2003). Mechanistically, it will be important to
determine if the role of Hsp70 in aiding protein import into mitochondria (Schmidt et al.,
2010) is related to improved mitochondrial function in sensory neurons and/or Schwann
cells and the recovery of sensation.
In summary, pharmacologically targeting molecular chaperones can be sufficiently
cytoprotective to reverse pre-existing functional and morphological deficits associated with
insensate DPN in diabetic mice. The finding that KU-32 promotes significant morphologic
recovery of iENFs argues against drug efficacy arising due solely to acute neurochemical
corrections that are sufficient to improve NCV in rodents (Calcutt, 2010; Calcutt et al.,
2009). Thus, modulating molecular chaperones may provide a novel therapeutic approach
that enables neurons and their supporting cells to better tolerate glycemic insults that
contribute to insensate neuropathy.
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KU-32 reverses deficits in NCV and sensory hypoalgesia. Swiss Webster mice were
rendered diabetic for 16 weeks and then treated with weekly doses of vehicle or 20 mg/kg
KU-32 for 10 weeks. (A) Ten weeks of KU-32 treatment significantly improved diabetes-
induced deficits in MNCV (solid bars, left axis) and SNCV (striped bars, right axis). *,
p<0.05 versus untreated control, ^, p<0.05 versus STZ + Veh. Four weeks after the
induction of diabetes, mechanical (B) and thermal (C) sensitivity were assessed biweekly.
After initiating KU-32 therapy, sensory measures were taken weekly. Sixteen weeks of
diabetes produced a significant decline in mechanical and thermal sensitivity which showed
a time-dependent improvement following weekly treatment with KU-32. *, p<0.05 versus
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time-matched Veh + Veh; ^, p<0.05 versus time matched STZ + Veh. Number of animals
per treatment is given in Table 1.
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Diabetes-induced decrease in iENF density is improved by KU-32 treatment. Swiss Webster
mice were rendered diabetic for 16 weeks, treated with weekly doses of vehicle or 20 mg/kg
KU-32 for 10 weeks and iENF density determined. Representative images (A) and
quantitative analysis (B) of iENF density. **, p<0.01 versus Veh + Veh; ^, p<0.05 versus
STZ + Veh. Scale bar, 40 µm. Arrows show example of iENFs (white) and dermal nerve
fibers (red) that were counted. (C) Thermal paw withdrawal latency was plotted against
iENF density for each animal and subjected to k-means cluster analysis. Circles indicate
cluster membership and identify that partial recovery of iENF density in diabetic mice
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treated with KU-32 was due to a subgroup in which recovery of thermal sensitivity and
iENF density were dissociated.
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KU-32 improves mitochondrial bioenergetics in diabetic sensory neurons. Swiss Webster
mice were rendered diabetic for 16 weeks, treated with weekly doses of vehicle or 20 mg/kg
KU-32 for 10 weeks and sensory neurons purified from lumbar DRG. (A) Representative
image of enriched culture of adult sensory neurons showing neurite outgrowth. Yellow
arrows show examples of contaminating non-neurons. Scale bar, 40 µm. (B) Explanation of
various measures of mitochondrial function in primary sensory neurons using the
extracellular flux technology. Arrows show times of addition of oligomycin and FCCP. (C)
Representative effect of oligomycin and FCCP on OCR in sensory neurons from obtained
from the various treatment groups. (D) Diabetes significantly altered ATP-coupled
respiration (solid bars) as determined by enhanced sensitivity to oligomycin and decreased
MRC (hatched bars). Both these parameters were significantly improved in diabetic mice
that received KU-32 therapy. *, p<0.05 versus time-matched Veh + Veh; ^, p<0.05 versus
time matched STZ + Veh. For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article.
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